articleTop 1% cited

Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

New England Journal of Medicine · 2006 · Vol. 355(1) · pp. 11–20

David Cunningham✉(Royal Marsden Hospital)William Allum(Royal Marsden Hospital)Sally Stenning(Medical Research Council)J N Thompson(Royal Marsden Hospital)Cornelis J.�H. van de Velde(Leiden University Medical Center)M. Nicolson(Aberdeen Royal Infirmary)J.H. Scarffe(The Christie Hospital)F. Lofts(St George's Hospital)Stephen Falk(At Bristol)Timothy Iveson(Southampton General Hospital)David B. Smith(Clatterbridge Cancer Centre NHS Foundation Trust)Ruth E. Langley(Medical Research Council)Monica Verma(Medical Research Council)Simon Weeden(Medical Research Council)Yu Jo Chua(Royal Marsden Hospital)

View via DOI Publisher page

Abstract

In patients with operable gastric or lower esophageal adenocarcinomas, a perioperative regimen of ECF decreased tumor size and stage and significantly improved progression-free and overall survival. (Current Controlled Trials number, ISRCTN93793971 [controlled-trials.com].).

Gastric Cancer Management and Outcomes Esophageal Cancer Research and Treatment Metastasis and carcinoma case studiesMedicineEpirubicinRegimenPerioperativeCisplatinChemotherapyCancerSurgeryInternal medicineAdenocarcinoma

MeSH terms

AdenocarcinomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCisplatinEsophageal NeoplasmsEsophagogastric JunctionFemaleFluorouracilGastrectomyHumansMaleMiddle AgedStomach Neoplasms

Citations

6,297

FWCI

127.44

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

The correlation between parity and incidence of premature rupture of membranes